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The consumption of botanicals for therapeutic purposes has increased significantly in recent years. Drug-
induced liver disease (DILI) is a frequent cause of acute liver injury, around 50% in the United States, and 
about 1% is secondary to the use of phytotherapeuticals and herbal supplies. Ruellia bahiensis, a plant 
species of the Acanthaceae family, is a tropical plant distributed in Northeastern Brazil. In folk medicine 
in the state of Bahia, the species is known as “mãe-boa” and is commonly used. L.S.S, a 23-year old, 
female, patient was admitted at University Hospital of Bahia-Brazil with signs and symptoms of acute 
hepatitis. She had made daily use of an herbal supply popularly known as “mãe-boa” for at least two 
years prescribed by a physician. Diagnostic investigation was negative for viral and autoimmune hepatitis, 
leptospirosis, dengue, and CMV (cytomegalovirus). The patient had to undergo liver transplantation. 
Explant revealed massive hepatic necrosis. According to histological findings, and after exclusion of 
other etiologies, liver damage was assigned to herbal supply. The prolonged use of Ruellia bahiensis 
infusions may have caused the liver dysfunction. 
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INTRODUCTION
The consumption of botanical agents for therapeutic 
purposes has grown exponentially in recent years in 
western countries (Veiga, Pinto, 2005). A recent study 
reveals that 42% of North Americans experience some 
form of alternative health care treatment, 12.5% of them 
make use of herbal agents and, in the last ten years, they 
accounted for 20% to 30% of patients with clinical liver 
injuries in health care services (Estes et al., 2003). 
In the United States, it is estimated that approximately 
2,000 people per year are diagnosed with fulminant 
hepatic failure (FHF): 13% of them due to idiosyncratic 
adverse reactions to drugs, while 10 to 22/1,000,000 
hospitalizations/per year are related to idiopathic hepatitis 
(Ostapowicz et al., 2002).
A research conducted by Dhiman et al. (1998) 
studied 204 patients diagnosed with acute liver failure. 
Among these, 15 (7.4%) suffered from DILI. Another 
study conducted in India, comprising 430 patients with 
FHF, demonstrated that 4.5% (19/430) of the cases were 
related to drugs (Acharya et al., 1996). In a series of 20 
patients with FHF referred to liver transplantation, 35% of 
cases had no identified cause other than herbal supplement 
use (Estes et al., 2003).
The mechanism by which herbal and phytotherapeutic 
agents cause liver damage is unclear. Drugs and chemical 
agents may act as direct hepatotoxins or the injury may 
be the result of idiosyncratic inflammatory reactions 
(Goldman, Auselio, 2005). A single drug can trigger 
toxic effects through different mechanisms. Although the 
toxicity of certain drugs is dose-related, the idiosyncratic 
drug-induced toxicity suggests marked environmental 
and host-related factors, such as age, use of alcoholic 
beverages, gender, preexisting liver and/or kidney diseases 
and genetic factors, such as enzymatic polymorphism. The 
genetically different isozymes of cytochrome (CYP) P450 
may partially explain the varied drug response (Schidt, 
Lee, 2005).
One of the probable mechanisms can be explained 
by biotransformation, which generally modifies a 
non-polar in a polar compound, followed by oxidative 
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pathways mediated by cytochromes (CYP) P-450. Another 
mechanism by which hepatotoxicity may occur would 
be through the involvement of glutathione S-transferase 
acetylating and alcohol dehydrogenase enzymes (Schidt, 
Lee, 2005).
The clinical features of severe hepatic failure 
are varied, which comprise hepatic encephalopathy, 
jaundice, coagulopathy, renal and circulatory dysfunction, 
hyperammonaemia (Keeffe, 2005).
In popular and traditional Brazilian medicine, and 
more specifically in the state of Bahia (northeast Brazil), 
a plant popularly known as “mãe-boa” is usually intended 
for women. It is used as an anti-inflammatory agent for 
the treatment of female genital tract diseases. Mãe-boa 
was identified as Ruellia bahiensis, a plant that belongs 
to the acanthaceae family. The genus Ruellia L. comprises 
about 150 species native to tropical and temperate 
North and South America (Da Silva et al., 2005). The 
well-recognized groups of secondary metabolites are 
flavonoids, lignans, coumarins, alkaloids, among others 
(Samy et al., 2015).
We hereafter describe a case of a young woman who 
has made continuous use of Ruellia bahiensis and ended 
up developing hepatic dysfunction, which required liver 
transplantation. 
Case report
A 23-year-old black female patient sought medical 
care complaining of abdominal pain, diaphoresis, nausea, 
and headaches. She denied the usage of illicit drugs but 
reported drinking on weekends and smoking occasionally. 
Moreover, she reported having seafood allergy.
She took oral contraceptive (levonorgestrel 0.15 
mg + ethinyl estradiol 0.03 mg) 4 years ago; 1 pill of 
prednisone a day upon seafood consumption. She reported 
sporadic use of acetylsalicylic acid and dipyrone for 
headaches. Regarding the use of herbal supplies, she 
sporadically ingested infusions of Peumus boldus (Chilean 
boldo) and Piper umbellatum (capeba) for abdominal 
pains during the last 3 months, as well as Ruellia bahiensis 
for 5 months.
On physical examination, the patient was markedly 
icteric, and reported to have abdominal pain, sweating, 
nausea, headaches, and drowsiness. Laboratory tests 
workup revealed AST = 1201 U/L (reference value 
[RV] = 15 -50 U/L), ALT = 1290 U/L (RV = 15-47 U/L), 
total bilirubin of 21.78 mg/dL (RV ≤ 1,10 mg/dL)), INR 
(international normalized ratio) of 2.31 (RV ≤ 1,2 ) and 
prothrombin time of 28% (RV ≥ 70 %). Additionally, 
the patient tested negative for: IgM Anti-HBc, HBsAg, 
Anti-HAV (IgM), Anti-HCV, Toxoplasmosis IgM, 
Cytomegalovirus IgM, leptospirosis IgM, dengue IgM, 
Herpes I and II (IgM), HIV I and II, Anti-nuclear Factor 
– anti smooth muscle, anti-LKM and antimitochondrial 
antibodies. 
The patient’s clinical status worsened after 
hospitalization with signs of acute liver failure. Two days 
after admission, the patient was submitted to orthotopic 
liver transplant. The histopathology of the explanted 
liver revealed extensive multilobular necrosis, with many 
apoptotic bodies. A mild mononuclear inflammatory 
infiltrate containing lymphocytes, few plasma cells and 
macrophages was observed. The bile duct had no injuries.
Considering the aforementioned drugs,  an 
interaction between the oral contraceptive and prednisone 
was identified, so that the contraceptive potentiates the 
effects of the corticosteroid (neurophysiological reactions, 
electrolyte disorders, hypertension, hyperglycemia), but 
no relation to liver damage could be found. Moreover, 
no interaction between Ruellia bahiensis vs. oral 
contraceptive and Ruellia bahiensis vs. prednisone has 
been described. 
With regard to Piper umbellatum and Peumus 
boldus, there are reports in the literature showing the 
association of these herbal infusions with hepatotoxicity. 
However, the patient used those herbs after the onset 
of signs and symptoms of FHF. According to Teschke, 
Schwarzenboeck and Hennermann’s algorithm (2008), 
causality between FHF and infusions of Ruellia bahiensis 
was possible.
DISCUSSION
This is the first reported and documented case of 
Fulminant Hepatic Failure probably caused by the use 
of Ruellia bahiensis infusions. According to studies, the 
use of botanical infusions for therapeutic purposes and 
the development of DILI secondary to herbal supplies 
are more frequently observed amongst women (Estes 
et al., 2003). The clinical features presented by the 
patient described are typical of fulminant hepatic failure, 
as corroborated by the laboratory tests and further 
anatomopathologic examination (Powel, 2005).
The viral serologies are essential in these cases, since 
the exposure to viral hepatitis A in Brazilian population 
is still high. The prevalence for hepatitis B is of 1% and 
for hepatitis C, 2%. However, these possibilities as well 
as other viral serologies were ruled out in our patient 
(Ferreira, Silveira, 2004), as they tested negative. 
Autoimmune hepatitis is characterized by the 
presence of autoantibodies, high levels of serum 
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immunoglobulins and frequent association with other 
autoimmune diseases (Lindsay, Hoofnagle, 2005). The 
diagnosis of autoimmune hepatitis is also based on 
histological findings. In the case reported, the histological 
findings were not consistent with this diagnosis, but with 
a toxic etiology aggression process.
Other causes of fulminant hepatitis, such as 
Budd-Chiari syndrome, Wilson’s disease and Reye’s 
syndrome, were excluded because the patient’s clinical 
outcome and laboratory tests did not characterize any of 
the aforementioned etiologies (Belay et al., 1990). Other 
disorders that may lead to FHF, such as fatty liver of 
pregnancy, hyperthermia, hypoxia, malignant infiltration 
and sepsis were also excluded (Goldman, Auselio, 2005).
Regarding the use of allopathic drugs, it is estimated 
that the chemical or drug-induced toxicity is associated 
with 25% to 30% of hepatopathy cases (Lindsay et al., 
2005). Among the drugs used by the patient, the oral 
contraceptive (levonorgestrel + ethinyl estradiol) should 
be taken into consideration, since it presents the ability 
to contribute to liver damage, especially complications 
of cholestasis, as described by Scheuer (1974). However, 
according to histological results, damage caused by 
steroids is mischaracterized, as it is defined by cholestasis 
(dilated canaliculi, brown granules in the cytoplasm of 
hepatocytes), some level of hepatic cell necrosis, lesions 
of the biliary ducts lesions, and polymorphonuclear 
leukocyte infiltration (Bhamidimarri, Schiff, 2013).
From the resul ts  obtained af ter  botanical 
identification of plant species, it is possible that the species 
responsible for the patient’s liver damage was Ruellia 
bahiensis. With regard to the use of other concomitant 
herbal infusions with Ruellia bahiensis, Peumus boldus 
was reported to be associated with the elevation of 
aminotransferases (Ruiz et al., 2008). However, in the 
reported case, Peumus boldus was not ingested daily and 
the beginning of its intake occurred after the onset of liver 
toxicity symptoms.
There has been no evidence regarding toxicity 
of Ruellia bahiensis and its association with fulminant 
hepatic failure. However, the patient’s habits of using 
herbal supplies may be an indicative of the occurrence of 
the damage, since the idiosyncratic drug-induced toxicity 
suggests important environmental and host-related factors, 
such as age, alcohol use, sex, preexisting hepatic disease, 
kidney disease and genetic factors, such as enzymatic 
polymorphism (Schidt, Lee, 2005).
As for the causality assessment between the 
possible use of Ruellia bahiensis infusions and FHF, the 
result obtained by applying the algorithms was classified 
as possible according to Teschke, Schwarzenboeck, 
Hennermann (2008). This result can be explained by the 
fact that some variables of this algorithm, such as the 
assessment of plasma drug concentration or the use of 
placebo for the evaluation of the use of herbal supplies 
are not part of routine health services activities in Brazil.
One of the proposals of the Teschke, Schwarzenboeck 
and Hennermann’s (2008) algorithm is that it questions the 
existence of Anti-HVE tests. However, even in our case, 
the fact that this test was not carried out is not of major 
importance, since epidemiological data do not suggest 
a relevant frequency of Hepatitis E in the country at 
issue. Another proposal raised in this algorithm is the re-
exposure of the patient to the drug. This is not applicable 
in our case either because the outcome of the reaction does 
not enable this analysis.
Acute liver failure is likely to affect the patient 
and is related to the use of Ruellia bahiensis, although 
fulminant hepatic failure secondary to the use of 
phytotherapeuticals is related to 1% of cases (Estes et 
al., 2003). This small percentage is associated with the 
absence of pharmacovigilance studies on herbal infusions, 
phytotherapy, which reflects the lack of research and 
knowledge about the use of plants and their relationship as 
an etiological agent for DILI cases. Therefore, the report 
indicates the relevance of advising patients that natural 
supplements are not harmless to health.
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